Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia — Stella

Home/Staphylococcus Aureus Endocarditis/

View on ClinicalTrials.gov

Recruiting

Back to Staphylococcus Aureus Endocarditis trials

Phase 4 — Post-approval study. The treatment has been approved, but researchers continue monitoring it in a large population over time.

Trial locations(1 site)

Canada

McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital), Montreal, Quebec

Key details

Phase

Post-approval study

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre

Collaborators

University of Melbourne

Enrollment target

~300 participants

Started

January 2026

Primary completion

January 2030

Age range

18 Years and older

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.